迈向焦虑障碍的精准医学:客观评估、风险预测、药物基因组学与药物重定位
该研究采用四步法发现焦虑障碍血液生物标志物:纵向个体内设计发现基因表达变化,收敛功能基因组学优先排序,独立队列验证,再独立队列测试临床效用。最佳证据标志物包括GAD1、NTRK3、ADRA2A等,按性别和诊断个体化可提高准确性,尤其女性。标志物可匹配现有药物并识别重定位候选药。
要点
- 采用纵向个体内设计发现焦虑状态相关血液基因表达变化。
- 最佳证据标志物包括GAD1、NTRK3、ADRA2A、FZD10、GRK4和SLC6A4。
- 标志物可用于匹配现有药物、测量治疗反应及识别重定位候选药。
核心结论
- 血液基因表达标志物可用于焦虑障碍的客观评估、风险预测和药物匹配。
- 按性别和诊断个体化可提高标志物预测焦虑严重状态的准确性,尤其女性。
研究设计与样本
- 研究采用四步法:纵向个体内设计发现、收敛功能基因组学优先排序、独立队列验证、另一独立队列测试临床效用。
- 发现与验证对象均为精神科受试者,比较自报低焦虑与高焦虑状态。
主要发现
- 最佳总体证据标志物为GAD1、NTRK3、ADRA2A、FZD10、GRK4和SLC6A4。
- 个体化方法按性别和诊断可提高单个标志物预测焦虑严重状态的准确性,尤其女性。
- 标志物可预测未来临床恶化(以焦虑为 contributory cause 的住院)。
关键数值与推荐
- 标志物可匹配现有药物包括丙戊酸盐、omega-3脂肪酸、氟西汀、锂盐、舍曲林、苯二氮䓬类和氯胺酮。
- 重定位候选药包括雌二醇、pirenperone、洛哌丁胺和丙吡胺。
临床怎么用
- 可利用血液基因表达标志物客观评估焦虑严重状态并预测未来临床恶化。
- 可根据标志物将患者匹配至现有药物并测量治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anxiety disorders are increasingly prevalent, affect people's ability to do things, and decrease quality of life. Due to lack of objective tests, they are underdiagnosed and sub-optimally treated, resulting in adverse life events and/or addictions. We endeavored to discover blood biomarkers for anxiety, using a four-step approach. First, we used a longitudinal within-subject design in individuals with psychiatric disorders to discover blood gene expression changes between self-reported low anxiety and high anxiety states. Second, we prioritized the list of candidate biomarkers with a Convergent Functional Genomics approach using other evidence in the field. Third, we validated our top biomarkers from discovery and prioritization in an independent cohort of psychiatric subjects with clinically severe anxiety. Fourth, we tested these candidate biomarkers for clinical utility, i.e. ability to predict anxiety severity state, and future clinical worsening (hospitalizations with anxiety as a contributory cause), in another independent cohort of psychiatric subjects. We showed increased accuracy of individual biomarkers with a personalized approach, by gender and diagnosis, particularly in women. The biomarkers with the best overall evidence were GAD1, NTRK3, ADRA2A, FZD10, GRK4, and SLC6A4. Finally, we identified which of our biomarkers are targets of existing drugs (such as a valproate, omega-3 fatty acids, fluoxetine, lithium, sertraline, benzodiazepines, and ketamine), and thus can be used to match patients to medications and measure response to treatment. We also used our biomarker gene expression signature to identify drugs that could be repurposed for treating anxiety, such as estradiol, pirenperone, loperamide, and disopyramide. Given the detrimental impact of untreated anxiety, the current lack of objective measures to guide treatment, and the addiction potential of existing benzodiazepines-based anxiety medications, there is a urgent need for more precise and personalized approaches like the one we developed.
引用
- Roseberry K, Le-Niculescu H, Levey DF, et al. Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry. 2023. PMID: 36878964. doi:10.1038/s41380-023-01998-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。